Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Carcinoma, Non-Small-Cell Lung"" wg kryterium: Temat


Tytuł :
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Autorzy :
Zhao Y; Department of Medical Oncology.; Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC.
Shi F; Department of Pathology, Beijing Shijitan Hospital, Capital Medical University.
Zhou Q; Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.
Li Y; Beijing Key Laboratory of Therapeutic Vaccines.
Wu J; Beijing Key Laboratory of Therapeutic Vaccines.
Wang R; Department of Emergency.
Song Q; Department of Clinical Epidemiology and Evidence-based Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Nov 06; Vol. 99 (45), pp. e23172.
Typ publikacji :
Journal Article
MeSH Terms :
B7-H1 Antigen/*biosynthesis
Carcinoma, Non-Small-Cell Lung/*metabolism
Carcinoma, Non-Small-Cell Lung/*mortality
Lung Neoplasms/*metabolism
Lung Neoplasms/*mortality
Aged ; B7-H1 Antigen/analysis ; Carcinoma, Non-Small-Cell Lung/chemistry ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/chemistry ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Autorzy :
Bian J; Department of Respiratory Medicine, Northern Jiangsu Province Hospital, Clinical Medical College of Yangzhou University, 28 Nan Tong Road, Yangzhou, 225001, People's Republic of China.
Yan K; Department of Neurosurgery, Northern Jiangsu Province Hospital, Clinical Medical College of Yangzhou University, Yangzhou, 225001, People's Republic of China.
Liu N; Department of Respiratory Medicine, Northern Jiangsu Province Hospital, Clinical Medical College of Yangzhou University, 28 Nan Tong Road, Yangzhou, 225001, People's Republic of China.
Xu X; Department of Respiratory Medicine, Northern Jiangsu Province Hospital, Clinical Medical College of Yangzhou University, 28 Nan Tong Road, Yangzhou, 225001, People's Republic of China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Oct; Vol. 146 (10), pp. 2621-2630. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*diagnostic imaging
Carcinoma, Non-Small-Cell Lung/*pathology
Fluorodeoxyglucose F18/*pharmacokinetics
Lung Neoplasms/*diagnostic imaging
Lung Neoplasms/*pathology
Neoplastic Cells, Circulating/*pathology
Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/metabolism ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/blood ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Neoplastic Cells, Circulating/metabolism ; Phenotype ; Positron Emission Tomography Computed Tomography/methods
Czasopismo naukowe
Tytuł :
Mutations in the exons of epidermal growth factor receptor gene are associated with clinicopathological features of lung cancer.
Autorzy :
Wan Y; Thoracic Surgery, The First Affiliated Hospital of Shenzhen University/ Thoracic Surgery, Shenzhen Second People's Hospital, Shenzhen, China.
Wang Y; Thoracic Surgery, The First Affiliated Hospital of Shenzhen University/ Thoracic Surgery, Shenzhen Second People's Hospital, Shenzhen, China.
Fang F; Thoracic Surgery, The First Affiliated Hospital of Shenzhen University/ Thoracic Surgery, Shenzhen Second People's Hospital, Shenzhen, China.
Wu G; Thoracic Surgery, The First Affiliated Hospital of Shenzhen University/ Thoracic Surgery, Shenzhen Second People's Hospital, Shenzhen, China.
Zhang M; Internal Medicine, Shenzhen Prevention and Treatment Center for Occupational Diseases, Shenzhen, China. Electronic address: .
Pokaż więcej
Źródło :
Asian journal of surgery [Asian J Surg] 2020 Oct; Vol. 43 (10), pp. 1037-1038. Date of Electronic Publication: 2020 Jul 31.
Typ publikacji :
Letter
MeSH Terms :
Genetic Association Studies*
Mutation*
Carcinoma, Non-Small-Cell Lung/*genetics
Carcinoma, Non-Small-Cell Lung/*pathology
Exons/*genetics
Genes, erbB-1/*genetics
Lung Neoplasms/*genetics
Lung Neoplasms/*pathology
Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/mortality ; Cell Proliferation/genetics ; Cell Transformation, Neoplastic/genetics ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Neovascularization, Pathologic/genetics ; Retrospective Studies ; Survival Rate ; Treatment Outcome
Opinia redakcyjna
Tytuł :
Primary tumor standardized uptake value (SUVmax) measured on F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.
Autorzy :
Hui Z; Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China.; National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China.; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, People's Republic of China.
Wei F; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China.; National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China.; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, People's Republic of China.
Ren H; Department of Radiology, Tangshan People's Hospital, Tangshan, 063001, Hebei Province, People's Republic of China.
Xu W; National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. .; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China. .; Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China. .
Ren X; Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China. .; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, People's Republic of China. .; National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. .; Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, People's Republic of China. .; Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China. .; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, People's Republic of China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Oct; Vol. 146 (10), pp. 2595-2605. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*diagnostic imaging
Carcinoma, Non-Small-Cell Lung/*metabolism
Fluorodeoxyglucose F18/*pharmacokinetics
Lung Neoplasms/*diagnostic imaging
Lung Neoplasms/*metabolism
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/surgery ; Chemotherapy, Adjuvant ; Female ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/surgery ; Male ; Middle Aged ; Neoadjuvant Therapy ; Positron Emission Tomography Computed Tomography ; Prognosis ; Radiopharmaceuticals/pharmacokinetics ; Survival Analysis
Czasopismo naukowe
Tytuł :
Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data.
Autorzy :
Passaro A; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. Electronic address: .
Attili I; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Morganti S; Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Del Signore E; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Gianoncelli L; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Spitaleri G; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Stati V; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Catania C; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Curigliano G; Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
de Marinis F; Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2020 Sep; Vol. 89, pp. 102085. Date of Electronic Publication: 2020 Jul 22.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*drug therapy
Lung Neoplasms/*pathology
Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Humans ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Tytuł :
The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer.
Autorzy :
Halley A; Amsterdam University College, Amsterdam, the Netherlands.; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, the Netherlands.
Leonetti A; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, the Netherlands.; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Gregori A; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, the Netherlands.
Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Deng DM; Department of Preventive Dentistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Amsterdam, the Netherlands.
Giovannetti E; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, the Netherlands.; Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy.
Peters GJ; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University, Amsterdam, the Netherlands .; Department of Biochemistry, Medical University of Gdansk, Gdańsk, Poland.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Sep; Vol. 40 (9), pp. 4807-4818.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*microbiology
Carcinoma, Non-Small-Cell Lung/*therapy
Lung Neoplasms/*microbiology
Lung Neoplasms/*therapy
Microbiota/*physiology
Anti-Bacterial Agents/therapeutic use ; Antineoplastic Agents/therapeutic use ; Bacteria/drug effects ; Bacteria/isolation & purification ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Humans ; Immunomodulation ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Microbiota/drug effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
Autorzy :
Bouhlel L; University Côte d'Azur, CHU of Nice, FHU OncoAge, department of pulmonary medicine and oncology, 30, voie Romaine, 06000 Nice, France.
Doyen J; University of Côte d'Azur, Centre Antoine-Lacassagne, Fédération Claude-Lalanne, department of radiation oncology, 33, avenue de Valombrose, 06189 Nice, France. Electronic address: .
Chamorey E; University of Côte d'Azur, Centre Antoine-Lacassagne, department of biostatistics, 33, avenue de Valombrose, 06189 Nice, France.
Poudenx M; University of Côte d'Azur, Centre Antoine-Lacassagne, department medical oncology, 33, avenue de Valombrose, 06189 Nice, France.
Ilie M; University of Côte d'Azur, CHU of Nice, department of pathology, 30, voie Romaine, 06000 Nice, France.
Gal J; University of Côte d'Azur, Centre Antoine-Lacassagne, department of biostatistics, 33, avenue de Valombrose, 06189 Nice, France.
Guigay J; University of Côte d'Azur, Centre Antoine-Lacassagne, department medical oncology, 33, avenue de Valombrose, 06189 Nice, France.
Benzaquen J; University Côte d'Azur, CHU of Nice, FHU OncoAge, department of pulmonary medicine and oncology, 30, voie Romaine, 06000 Nice, France.
Marquette CH; University Côte d'Azur, CHU of Nice, FHU OncoAge, department of pulmonary medicine and oncology, 30, voie Romaine, 06000 Nice, France.
Berthet JP; University of Côte d'Azur, CHU of Nice, department of thoracic surgery, 30, voie Romaine, 06000 Nice, France.
Mouroux J; University of Côte d'Azur, CHU of Nice, department of thoracic surgery, 30, voie Romaine, 06000 Nice, France.
Schiappa R; University of Côte d'Azur, Centre Antoine-Lacassagne, department of biostatistics, 33, avenue de Valombrose, 06189 Nice, France.
Padovani B; University of Côte d'Azur, CHU of Nice, department of radiology, 30, voie Romaine, 06000 Nice, France.
Hofman P; University of Côte d'Azur, CHU of Nice, department of pathology, 30, voie Romaine, 06000 Nice, France.
Otto J; University of Côte d'Azur, Centre Antoine-Lacassagne, department medical oncology, 33, avenue de Valombrose, 06189 Nice, France.
Pokaż więcej
Źródło :
Bulletin du cancer [Bull Cancer] 2020 Sep; Vol. 107 (9), pp. 946-958. Date of Electronic Publication: 2020 Jul 06.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*mortality
Lung Neoplasms/*drug therapy
Lung Neoplasms/*mortality
Nivolumab/*adverse effects
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/therapeutic use ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/immunology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Nivolumab/therapeutic use ; Progression-Free Survival ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments.
Autorzy :
Zhao X; Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang N
Zhang H
Liu P
Ma J
Hu C
Liu X
Hou T
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Nov 13; Vol. 99 (46), pp. e23150.
Typ publikacji :
Journal Article
MeSH Terms :
Adenocarcinoma of Lung*/blood
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/pathology
Carcinoma, Non-Small-Cell Lung*/blood
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
ErbB Receptors/*genetics
Fibrinogen/*analysis
Protein Kinase Inhibitors/*therapeutic use
Serum Albumin, Human/*analysis
Biomarkers/blood ; Blood Cell Count/methods ; Female ; Humans ; Male ; Middle Aged ; Mutation ; Predictive Value of Tests ; Prognosis ; Progression-Free Survival
Czasopismo naukowe
Tytuł :
Should WEE(1) CHK(1) in on the FAM(122A)ily?
Autorzy :
Caeser R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sen T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2020 Nov 05; Vol. 80 (3), pp. 377-378.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Checkpoint Kinase 1/genetics ; Humans ; Phosphorylation ; Protein Kinases/metabolism
Czasopismo naukowe
Tytuł :
Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
Autorzy :
SjØgren K; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
Jacobsen KA; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.
GrØnberg BH; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway.; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Halvorsen TO; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, NTNU, Trondheim, Norway .; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Nov; Vol. 40 (11), pp. 6399-6406.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Deoxycytidine/*adverse effects
Lung Neoplasms/*diagnostic imaging
Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Lung Neoplasms/epidemiology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Time Factors
Czasopismo naukowe
Tytuł :
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Autorzy :
Cortellini A; Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy. .; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. .
Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.; Department of Medicine and Surgery, University of Parma, Parma, Italy.
Banna GL; Oncology Department, United Lincolnshire Hospital NHS Trust, Lincoln, UK.
Cappuzzo F; Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy.
Aerts JGJV; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
Barbieri F; Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.
Giusti R; Medical Oncology Unit, Sant' Andrea Hospital fo Rome, Rome, Italy.
Bria E; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Cortinovis D; Medical Oncology, Ospedale San Gerardo, Monza, Italy.
Grossi F; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Migliorino MR; Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
Galetta D; Thoracic Oncology Unit, Clinical Cancer Center, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Passiglia F; Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, TO, Italy.
Santini D; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Berardi R; Oncology Clinic, Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Ancona, Italy.
Morabito A; Thoracic Medical Oncology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Naples, Italy.
Genova C; Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Mazzoni F; Department of Oncology, Careggi University Hospital, Florence, Italy.
Di Noia V; Medical Oncology, University Hospital of Foggia, Foggia, Italy.
Signorelli D; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Tuzi A; Medical Oncology, ASST-Sette Laghi, Varese, Italy.
Gelibter A; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.
Marchetti P; Medical Oncology Unit, Sant' Andrea Hospital fo Rome, Rome, Italy.; Medical Oncology (B), Policlinico Umberto I, 'Sapienza' University of Rome, Rome, Italy.; Department of Clinical and Molecular Medicine, 'Sapienza' University of Rome, Rome, Italy.
Macerelli M; Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy.
Rastelli F; Medical Oncology, Fermo Area Vasta 4, Fermo, Italy.
Chiari R; Medical Oncology, Ospedali Riuniti Padova Sud 'Madre Teresa Di Calcutta', Monselice, Italy.
Rocco D; Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy.
Gori S; Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy.
De Tursi M; Department of Medical, Oral and Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Chieti, Italy.
Mansueto G; Medical Oncology, F. Spaziani Hospital, Frosinone, Italy.
Zoratto F; Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy.
Santoni M; Department of Oncology, Macerata Hospital, Macerata, Italy.
Tudini M; Medical Oncology, AV2 Fabriano ASUR Marche, Fabriano, Italy.
Rijavec E; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Filetti M; Medical Oncology Unit, Sant' Andrea Hospital fo Rome, Rome, Italy.
Catino A; Thoracic Oncology Unit, Clinical Cancer Center, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Pizzutilo P; Thoracic Oncology Unit, Clinical Cancer Center, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
Sala L; Medical Oncology, Ospedale San Gerardo, Monza, Italy.
Citarella F; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Marco R; Medical Oncology, Campus Bio-Medico University, Rome, Italy.
Torniai M; Oncology Clinic, Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Ancona, Italy.
Cantini L; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.; Oncology Clinic, Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Ancona, Italy.
Targato G; Department of Oncology, University Hospital Santa Maria Della Misericordia, Udine, Italy.
Sforza V; Thoracic Medical Oncology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Naples, Italy.
Nigro O; Medical Oncology, ASST-Sette Laghi, Varese, Italy.
Ferrara MG; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.; Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
D'Argento E; Comprehensive Cancer Center, Fondazione Policlinico Universitario 'A. Gemelli' IRCCS, Rome, Italy.
Buti S; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Bordi P; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Antonuzzo L; Department of Oncology, Careggi University Hospital, Florence, Italy.
Scodes S; Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy.
Landi L; Department of Oncology and Hematology, AUSL Romagna, Ravenna, Italy.
Guaitoli G; Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.
Baldessari C; Department of Oncology and Hematology, Modena University Hospital, Modena, Italy.
Della Gravara L; Pneumo-Oncology Unit, Monaldi Hospital, Naples, Italy.
Dal Bello MG; Lung Cancer Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Belderbos RA; Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The Netherlands.
Bironzo P; Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, TO, Italy.
Carnio S; Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, TO, Italy.
Ricciardi S; Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
Grieco A; Pneumo-Oncology Unit, St. Camillo-Forlanini Hospital, Rome, Italy.
De Toma A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Proto C; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Friedlaender A; Oncology Department, University Hospital of Geneva, Geneva, Switzerland.
Cantale O; Oncology Department, United Lincolnshire Hospital NHS Trust, Lincoln, UK.
Ricciuti B; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Division of Medical Oncology, S.Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy.
Addeo A; Oncology Department, University Hospital of Geneva, Geneva, Switzerland.
Metro G; Department of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.
Ficorella C; Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Porzio G; Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy.; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy.
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Nov; Vol. 69 (11), pp. 2209-2221. Date of Electronic Publication: 2020 May 30.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; B7-H1 Antigen/biosynthesis ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Conversion from thoracoscopic to open pneumonectomy is not associated with short- or long-term mortality.
Autorzy :
Hue JJ; Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, OH.
Linden PA; Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, OH.
Bachman KC; Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, OH.
Worrell SG; Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, OH.
Gray KE; Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, OH.
Towe CW; Division of Thoracic and Esophageal Surgery, Department of Surgery, University Hospitals Cleveland Medical Center and Case Western Reserve School of Medicine, OH. Electronic address: .
Pokaż więcej
Źródło :
Surgery [Surgery] 2020 Nov; Vol. 168 (5), pp. 948-952. Date of Electronic Publication: 2020 Jul 15.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Non-Small-Cell Lung/*surgery
Lung Neoplasms/*surgery
Pneumonectomy/*methods
Thoracoscopy/*methods
Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Lymph Nodes/pathology ; Male ; Middle Aged ; Thoracotomy
Czasopismo naukowe
Tytuł :
ZNF300 promotes chemoresistance and aggressive behaviour in non-small-cell lung cancer.
Autorzy :
Yu S; Institute of Human Respiratory Disease, Xinqiao Hospital, the Army Medical University (Third Military Medical University), Chongqing, China.; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Ao Z; Department of Respiratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Wu Y; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Song L; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Zhang P; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Li X; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Liu M; Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Qian P; Institute of Human Respiratory Disease, Xinqiao Hospital, the Army Medical University (Third Military Medical University), Chongqing, China.
Zhang R; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Li X; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Chen Y; Institute of Human Respiratory Disease, Xinqiao Hospital, the Army Medical University (Third Military Medical University), Chongqing, China.
Wang X; Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Biomedical Research Institute, Hubei University of Medicine, Shiyan, China.
Wang X; Institute of Biomedical Research, Hubei University of Medicine, Shiyan, China.
Ruan X; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Qian G; Institute of Human Respiratory Disease, Xinqiao Hospital, the Army Medical University (Third Military Medical University), Chongqing, China.
Ji F; Department of Medical Biology, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.; Hubei Key Laboratory of Embryonic Stem Cell Research, School of Basic Medical Science, Hubei University of Medicine, Shiyan, China.
Pokaż więcej
Źródło :
Cell proliferation [Cell Prolif] 2020 Nov; Vol. 53 (11), pp. e12924. Date of Electronic Publication: 2020 Oct 19.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*/drug effects
Transcriptome*/drug effects
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Repressor Proteins/*genetics
Animals ; Antineoplastic Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cisplatin/pharmacology ; DNA Methylation/drug effects ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Male ; Mice, Inbred BALB C ; Middle Aged ; Repressor Proteins/metabolism ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.
Autorzy :
Hakozaki T; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan.
Hosomi Y; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. .
Kitadai R; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan.
Kitagawa S; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan.
Okuma Y; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan.; Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1Tsukiji, Chuo, Tokyo, 105-0045, Japan.
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Nov; Vol. 146 (11), pp. 2957-2966. Date of Electronic Publication: 2020 May 27.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*drug therapy
Lung Neoplasms/*pathology
Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Autorzy :
Provencio M; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. Electronic address: .
Nadal E; Institut Català d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Insa A; Fundación INCLIVA, Hospital Clínico Universitario de Valencia, Valencia, Spain.
García-Campelo MR; Hospital Universitario A Coruña, A Coruña, Spain.
Casal-Rubio J; Hospital Universitario de Vigo, Pontevedra, Spain.
Dómine M; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Majem M; Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
Rodríguez-Abreu D; Hospital Insular de Gran Canaria, Las Palmas, Spain.
Martínez-Martí A; Hospital Universitario e Instituto de Oncología Vall d'Hebron (VHIO), Barcelona, Spain.
De Castro Carpeño J; Hospital Universitario La Paz, Madrid, Spain.
Cobo M; Hospital Universitario Regional de Málaga, Málaga, Spain.
López Vivanco G; Hospital Universitario Cruces, Barakaldo, Spain.
Del Barco E; Hospital Universitario de Salamanca, Salamanca, Spain.
Bernabé Caro R; Hospital Universitario Virgen del Rocio, Seville, Spain.
Viñolas N; Hospital Clínic de Barcelona, Barcelona, Spain.
Barneto Aranda I; Hospital Universitario Reina Sofia, Córdoba, Spain.
Viteri S; Instituto Oncológico Dr Rosell, Hospital Universitari Dexeus-Grupo Quironsalud, Barcelona, Spain.
Pereira E; Spanish Lung Cancer Group, Barcelona, Spain.
Royuela A; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Casarrubios M; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Salas Antón C; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Parra ER; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Wistuba I; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Calvo V; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Laza-Briviesca R; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Romero A; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Massuti B; Hospital General de Alicante, Alicante, Spain.
Cruz-Bermúdez A; Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. 1413-1422. Date of Electronic Publication: 2020 Sep 24.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carboplatin/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Nivolumab/*administration & dosage
Aged ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/immunology ; Carboplatin/adverse effects ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/pathology ; Carcinoma, Non-Small-Cell Lung/surgery ; Female ; Humans ; Male ; Middle Aged ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Nivolumab/adverse effects ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival ; Spain/epidemiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
Autorzy :
Zhou H; Department of Thoracic Oncology, West China Hospital/West China Medical Center, Sichuan University, Chengdu, China.
Sun Y; Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China.
Xiu W; Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Han J; Department of Thoracic Oncology, West China Hospital/West China Medical Center, Sichuan University, Chengdu, China.
Zhong L; Department of Thoracic Oncology, West China Hospital/West China Medical Center, Sichuan University, Chengdu, China.
Suo J; Department of Thoracic Oncology, West China Hospital/West China Medical Center, Sichuan University, Chengdu, China.
Wei H; Department of Thoracic Oncology, West China Hospital/West China Medical Center, Sichuan University, Chengdu, China.
Wang Y; Department of IVF, West China 2nd Hospital, Sichuan University, Chengdu, China.
Zhu J; Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Nov; Vol. 146 (11), pp. 2979-2988. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*drug therapy
Lung Neoplasms/*pathology
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/mortality ; Disease Progression ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Targeting MET amplification in EGFR-mutant non-small-cell lung cancer.
Autorzy :
Rosell R; Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: .
Chaib I; Laboratory of Cellular and Molecular Biology, Institute for Health Science Research Germans Trias I Pujol (IGTP), Badalona, Spain.
Santarpia M; Medical Oncology Unit, AOU Policlinico G Martino, Department of Human Pathology, University of Messina, Messina, Italy.
Pokaż więcej
Źródło :
The Lancet. Respiratory medicine [Lancet Respir Med] 2020 Nov; Vol. 8 (11), pp. 1068-1070. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
ErbB Receptors/genetics ; Gefitinib ; Humans ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł :
Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
Autorzy :
Arcidiacono F; Radiotherapy Oncology Centre, 'S. Maria' Hospital, Terni, Italy.
Aristei C; Department of Surgical and Biomedical Science, Radiotherapy Oncology Centre, University of Perugia and 'Santa Maria della Misericordia' Hospital, Perugia, Italy.
Marchionni A; Department of Surgical and Biomedical Science, Radiotherapy Oncology Centre, University of Perugia and 'Santa Maria della Misericordia' Hospital, Perugia, Italy.
Italiani M; Radiotherapy Oncology Centre, 'S. Maria' Hospital, Terni, Italy.
Fulcheri CPL; Radiotherapy Oncology Centre, 'Santa Maria della Misericordia' Hospital, Perugia, Italy.
Saldi S; Radiotherapy Oncology Centre, 'Santa Maria della Misericordia' Hospital, Perugia, Italy.
Casale M; Radiotherapy Oncology Centre, 'S. Maria' Hospital, Terni, Italy.
Ingrosso G; Department of Surgical and Biomedical Science, Radiotherapy Oncology Centre, University of Perugia and 'Santa Maria della Misericordia' Hospital, Perugia, Italy.
Anselmo P; Radiotherapy Oncology Centre, 'S. Maria' Hospital, Terni, Italy.
Maranzano E; Radiotherapy Oncology Centre, 'S. Maria' Hospital, Terni, Italy.
Pokaż więcej
Źródło :
The British journal of radiology [Br J Radiol] 2020 Nov 01; Vol. 93 (1115), pp. 20200645. Date of Electronic Publication: 2020 Sep 02.
Typ publikacji :
Journal Article
MeSH Terms :
Adrenal Gland Neoplasms/*radiotherapy
Carcinoma, Non-Small-Cell Lung/*radiotherapy
Lung Neoplasms/*pathology
Radiosurgery/*methods
Radiotherapy, Intensity-Modulated/*methods
Small Cell Lung Carcinoma/*radiotherapy
Adrenal Gland Neoplasms/mortality ; Adrenal Gland Neoplasms/secondary ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; Combined Modality Therapy/methods ; Dose Fractionation, Radiation ; Dose-Response Relationship, Radiation ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Small Cell Lung Carcinoma/mortality ; Small Cell Lung Carcinoma/secondary
Czasopismo naukowe
Tytuł :
Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
Autorzy :
Kim SH; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Choi CM; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Lee DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Kim SW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Yoon S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Kim WS; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Ji W; Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. .
Lee JC; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Nov; Vol. 146 (11), pp. 3025-3036. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Nivolumab/*therapeutic use
Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Progression ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
Autorzy :
Lathwal A; Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi, Okhla Industrial Estate, Phase III (Near Govind Puri Metro Station), A-302 (R&D Block), New Delhi, 110020, India.
Kumar R; Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh, India.
Arora C; Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi, Okhla Industrial Estate, Phase III (Near Govind Puri Metro Station), A-302 (R&D Block), New Delhi, 110020, India.
Raghava GPS; Department of Computational Biology, Indraprastha Institute of Information Technology-Delhi, Okhla Industrial Estate, Phase III (Near Govind Puri Metro Station), A-302 (R&D Block), New Delhi, 110020, India. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2020 Nov; Vol. 146 (11), pp. 2743-2752. Date of Electronic Publication: 2020 Jul 14.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Carcinoma, Non-Small-Cell Lung/*mortality
Lung Neoplasms/*genetics
Lung Neoplasms/*mortality
Carcinoma, Non-Small-Cell Lung/pathology ; Gene Expression Profiling/methods ; Humans ; Lung Neoplasms/pathology ; Prognosis ; Transcriptome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies